1. O'Connor L, Monroe A, Ji Y, Baskaran A, et al.
   Longitudinal trends in copy-years viremia associated with mpox acquisition but not mpox severity in people with HIV.
   AIDS 2026.
   


2. Koss CA, Kamya MR, Nyabuti M, Okochi H, et al.
   Sex differences in long-acting cabotegravir trough concentrations in the SEARCH study in Kenya and Uganda.
   AIDS 2026.
   


3. Tiwari R, Collett BR, Oucho I, Otieno C, et al.
   Changes in neurodevelopmental outcomes from 24 to 36 months among children HIV-exposed uninfected (CHEU) and HIV-unexposed (CHU).
   AIDS 2026.
   


4. Lefebvre S, Goujard C, Meyer L, Durier C, et al.
   Reframing analytical treatment interruption through participants' and decliners' eyes: insights from an HIV remission trial.
   AIDS 2026.
   


5. Liu H, He Y, Yang T, Cai L, et al.
   Efficacy and Safety of Albuvirtide Plus Dolutegravir or Dolutegravir/Lamivudine in Hospitalized People with Advanced AIDS: A Retrospective Real-World Study.
   AIDS Res Hum Retroviruses 2026.
   


6. Etienney I, Singh D, Ressiot E, Didelot JM, et al.
   Evolution of Untreated Anal High-grade Squamous Intraepithelial Lesions in High-risk Men: A Prospective 5-year Clinical Follow-up in the ANRS-EP57-APACHES study.
   Clin Infect Dis 2026.
   


7. .
   Correction to: Low Trauma Fractures in People With HIV: Longitudinal Time Trends in the Swiss HIV Cohort Study, 2009-2022.
   Clin Infect Dis 2026.
   


8. .
   Correction to: Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance.
   Clin Infect Dis 2026.
   


9. McManus KA, Killelea A, Horn T.
   Clinical Excellence Amidst Fiscal Erosion: ADAP and the Ending the HIV Epidemic Initiative.
   Clin Infect Dis 2026.
   


10. McCrary LM, Curtis MR, Kelly JC, Elrod-Gallegos J, et al.
    Real-World Experience of Hepatitis C Treatment With Glecaprevir-Pibrentasvir During Pregnancy.
    Clin Infect Dis 2026.
    


11. Shah A, Sacdalan C, Gorelick R, Macmath D, et al.
    Preferential Reservoir Seeding in HPV16-Specific CD4-T-Cells During HIV-1 Acute and Chronic Infection.
    J Infect Dis 2026.
    


12. Lamcaj S, Cole E, Hiner C, Santos Bravo M, et al.
    Enhancing HIV-1-specific CAR-T cell functional activity by treatment with a novel cytokine-based scaffold with IL-15 superagonist and TGF-beta-neutralizing activity.
    J Virol 2026.
    


13. Kilroy JM, Deokar AA, Patalano S, Fuxman Bass JI, et al.
    Intragenic transcription from defective HIV proviruses triggers interferon responses in myeloid cells.
    J Virol 2026.
    


14. Colson AE, Kumar PN, Ruane PJ, Chetchotisakd P, et al.
    Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.
    Lancet 2026.
    


15. Del Mar Arcos M, Arribas JR.
    Once-weekly oral antiretroviral therapy for HIV.
    Lancet 2026.
    


16. Teufel F, Chandiwana N, Shivashankar R, Manne-Goehler J, et al.
    Global access to different classes of diabetes medicines: a framework for targeted policy actions.
    Nat Med 2026.
    

Display articles in

• Abstract format